Neoadjuvant meds for HER2+ breast cancer
Approximately 25% to 30% of breast cancers are the result of the overexpression of the HER2 gene.
Approximately 25% to 30% of breast cancers are the result of the overexpression of the HER2 gene.
Researchers have begun to question whether or not cognitive changes are a direct result of chemotherapy, or from the cancer itself.